Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3–ABCB1 Signaling in Hepatocellular Carcinoma

Lenvatinib is an inhibitor of multiple receptor tyrosine kinases that was recently authorized for first-line treatment of hepatocellular carcinoma (HCC). However, the clinical benefits derived from lenvatinib are limited, highlighting the urgent need to understand mechanisms of resistance. We report...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Beiyuan, Zou, Tiantian, Qin, Wei, Shen, Xiaotian, Su, Yinghan, Li, Jianhua, Chen, Yang, Zhang, Ze, Sun, Haoting, Zheng, Yan, Wang, Chao-Qun, Wang, Zhengxin, Li, Tian-En, Wang, Shun, Zhu, Le, Wang, Xufeng, Fu, Yan, Ren, Xudong, Dong, Qiongzhu, Qin, Lun-Xiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574378/
https://www.ncbi.nlm.nih.gov/pubmed/36066408
http://dx.doi.org/10.1158/0008-5472.CAN-21-4140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574378/
https://www.ncbi.nlm.nih.gov/pubmed/36066408
http://dx.doi.org/10.1158/0008-5472.CAN-21-4140

Ejemplares similares